SEC Company Response from COLLEGIUM PHARMACEUTICAL, INC (COLL) (CIK 0001267565) (COLL) — Mar 27, 2020
COLLEGIUM PHARMACEUTICAL, INC (COLL) (CIK 0001267565)
Date: March 27, 2020 · CIK: 0001267565 · Accession: 0001104659-20-039524
AI Filing Summary & Sentiment
File numbers found in text: 333-237200
Letter
Collegium Pharmaceutical, Inc.
100 Technology Center Drive, Suite 300
Stoughton, MA 02072
March 27, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Collegium Pharmaceutical, Inc.
Registration Statement on Form S-3
Filed March 16, 2020 (File No. 333-237200)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Collegium Pharmaceutical, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-237200) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 PM, eastern time, on March 30, 2020, or as soon as thereafter as is practicable.
Please contact Jennifer L. Porter, Esq. of Pepper Hamilton LLP, counsel to the Company, at (215) 981-4339 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]
Very truly yours,
COLLEGIUM PHARMACEUTICAL, INC.
Show Raw Text
CORRESP
1
filename1.htm
Collegium Pharmaceutical, Inc.
100 Technology Center Drive, Suite 300
Stoughton, MA 02072
March 27, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Collegium Pharmaceutical, Inc.
Registration Statement on Form S-3
Filed March 16, 2020 (File No. 333-237200)
Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended, Collegium Pharmaceutical, Inc. (the “Company”) hereby
requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-237200) (the
“Registration Statement”) be accelerated so that the Company’s Registration Statement will become
effective at 4:01 PM, eastern time, on March 30, 2020, or as soon as thereafter as is practicable.
Please contact Jennifer
L. Porter, Esq. of Pepper Hamilton LLP, counsel to the Company, at (215) 981-4339 to provide notice of effectiveness, or if
you have any questions or comments concerning this request.
[Remainder of the page intentionally
left blank]
Very truly yours,
COLLEGIUM PHARMACEUTICAL, INC.
By:
/s/ Shirley R. Kuhlmann
Name:
Shirley R. Kuhlmann
Title:
Executive Vice President, General Counsel and Secretary
Collegium Pharmaceutical, Inc.
— Acceleration Letter